10-Q: Q2 2024 Earnings Report
8-K: Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
4: Statement of changes in beneficial ownership of securities-Officer Hooftman Leon
3: Initial statement of beneficial ownership of securities-Officer Hooftman Leon
8-K: Current report
8-K: Current report
Barinthus Biotherapeutics | 8-K: Current report
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wright Robin
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director DAWES KAREN A
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Scheeren Joseph
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Phillips Anne M.
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hammacher Alex
Barinthus Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Morgon Pierre A.
Barinthus Biotherapeutics | 8-K/A: Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Biotherapeutics | 10-Q: Q1 2024 Earnings Report
Barinthus Biotherapeutics | 8-K: Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Biotherapeutics | 8-K: Current report
Barinthus Biotherapeutics | ARS: Annual Report to Security Holders
Barinthus Biotherapeutics | DEFA14A: Others
Barinthus Biotherapeutics | DEF 14A: Definitive information statements
No Data